Minerva Neurosciences (NERV) Announces Quarterly Earnings Results, Misses Estimates By $0.06 EPS

Minerva Neurosciences (NASDAQ:NERV) posted its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.06), MarketWatch Earnings reports.

NASDAQ:NERV opened at $7.19 on Tuesday. Minerva Neurosciences has a 1 year low of $5.80 and a 1 year high of $12.95.

Several equities analysts recently commented on the company. BidaskClub upgraded Minerva Neurosciences from a “hold” rating to a “buy” rating in a research note on Friday, January 11th. ValuEngine upgraded Minerva Neurosciences from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Zacks Investment Research upgraded Minerva Neurosciences from a “hold” rating to a “buy” rating and set a $7.25 price objective on the stock in a research note on Tuesday, February 5th.

An institutional investor recently raised its position in Minerva Neurosciences stock. Geode Capital Management LLC grew its stake in shares of Minerva Neurosciences Inc (NASDAQ:NERV) by 16.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 357,817 shares of the biopharmaceutical company’s stock after acquiring an additional 49,445 shares during the period. Geode Capital Management LLC owned 0.92% of Minerva Neurosciences worth $2,411,000 at the end of the most recent reporting period. Institutional investors own 76.11% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Minerva Neurosciences (NERV) Announces Quarterly Earnings Results, Misses Estimates By $0.06 EPS” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://sportsperspectives.com/2019/05/07/minerva-neurosciences-nerv-announces-quarterly-earnings-results-misses-estimates-by-0-06-eps.html.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

Further Reading: Dividend

Earnings History for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.